$23.69
-0.41(-1.70%)
Mkt Cap $2.9B
$12.59
$31.20
52-Week Range
At A Glance
1
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
2
Most recently: of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (2026-02-25).
$2.9B
Market Cap
$364M
Revenue
-$16M
Net Income
Employees342
Fundamentals
How The Business Makes Money
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001787306
ISINUS03969K1088
CUSIP03969K108
Phone805 418 5006
Address3027 Townsgate Road, Westlake Village, CA, 91361, US
SEC EDGAR